Amgen (AMGN) vs Regeneron Pharmaceuticals (REGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Amgen (AMGN) has outperformed Regeneron Pharmaceuticals (REGN) over the past year, gaining 38.3% versus a gain of 31.2%. Over five years, AMGN leads with a +96.0% price change compared with +33.7% for REGN. Amgen is the larger company by market cap ($220.28 billion vs $76.14 billion), about 2.9 times the size.
On valuation, Regeneron Pharmaceuticals trades at a lower forward P/E (12.0x vs 16.6x for Amgen). Amgen offers the higher dividend yield (2.41% vs 0.49%). Regeneron Pharmaceuticals converts more of its revenue into profit, with a net margin of 31.4% versus 21.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMGN | REGN |
|---|---|---|
| Share price | $407.44 | $739.57 |
| Market cap | $220.28B | $76.14B |
| 1-day change | -1.37% | -0.34% |
| YTD return | +24.48% | -4.18% |
| 1-year return | +38.29% | +31.16% |
| 5-year return | +96.04% | +33.68% |
| P/E ratio (TTM) | 25.31 | 18.29 |
| Forward P/E | 16.64 | 11.99 |
| EPS (TTM) | $16.10 | $40.44 |
| Dividend yield | 2.41% | 0.49% |
| Annual dividend | $9.80 | $3.64 |
| Revenue (latest FY) | $36.75B | $14.34B |
| Revenue growth (YoY) | +9.95% | +0.99% |
| Net income (latest FY) | $7.71B | $4.50B |
| Gross margin | 67.25% | — |
| Operating margin | 24.71% | 24.95% |
| Net margin | 20.98% | 31.41% |
| 52-week high | $447.03 | $859.34 |
| 52-week low | $288.00 | $541.00 |
| Distance from 52-week high | -8.86% | -13.94% |
| Analyst consensus | hold | buy |
| Avg. price target upside | -3.92% | +15.77% |
| Average volume | 2.73M | 736.98K |
| Shares outstanding | 540.63M | 101.14M |
| Employees | 31,500 | 15,410 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Amgen is about 2.9 times larger than Regeneron Pharmaceuticals by market value ($220.28B vs $76.14B).
- Amgen trades at a higher earnings multiple (25.3x vs 18.3x trailing P/E).
- Amgen offers a meaningfully higher dividend yield (2.41% vs 0.49%).
- Regeneron Pharmaceuticals is more profitable, keeping 31.4 cents of every revenue dollar as net income versus 21.0 cents for Amgen.
- Amgen grew revenue faster in its latest fiscal year (+9.95% vs +0.99%).
About Amgen
AMGN stock →Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 31,500 employees
About Regeneron Pharmaceuticals
REGN stock →Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide.
Health Care · Biotechnology: Pharmaceutical Preparations · 15,410 employees
AMGN vs REGN FAQ
Which is bigger, Amgen or Regeneron Pharmaceuticals?
Amgen (AMGN) is larger, with a market capitalization of $220.28B compared with $76.14B for Regeneron Pharmaceuticals (REGN).
Which stock has performed better over the past year, AMGN or REGN?
AMGN returned +38.29% over the past 12 months, compared with +31.16% for REGN (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, AMGN or REGN?
REGN has the lower trailing P/E at 18.3, versus 25.3 for AMGN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Amgen or Regeneron Pharmaceuticals?
Amgen has the higher yield at 2.41%, compared with 0.49% for Regeneron Pharmaceuticals.
Are Amgen and Regeneron Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Amgen and Biotechnology: Pharmaceutical Preparations for Regeneron Pharmaceuticals.